🔻 ALL 50 STATES JUST SIGNED ON — AND ONE NUMBER BURIED INSIDE THE ANNOUNCEMENT SHOULD GET EVERY AMERICAN’S ATTENTION: $529 BILLION.

While Washington is consumed by elections, Iran, China and the daily political fight, a major change involving prescription-drug prices just moved across the entire United States.

On September 18, President Donald Trump announced that all 50 states will participate in the GENEROUS Medicaid drug-pricing model.

The idea is simple enough to understand: Medicaid should not be forced to pay dramatically more for certain medicines than wealthy countries overseas. Under the model, participating manufacturers provide supplemental rebates designed to bring Medicaid’s net prices toward what the administration describes as Most Favored Nation pricing — essentially benchmarking them against lower prices available internationally.

Now look at the scale.

50 STATES.
70+ MILLION PEOPLE COVERED BY MEDICAID/CHIP.
$529 BILLION IN PROJECTED FEDERAL SAVINGS OVER 10 YEARS.

That final number is the administration’s estimate — not $529 billion already saved — and that distinction matters.

The announcement also doesn’t mean every American prescription suddenly becomes cheaper tomorrow. The program concerns Medicaid, manufacturers must participate for their drugs to be covered by the model, and outside health-policy experts say more transparency and data will be needed to determine how much Americans and taxpayers ultimately save.

But the underlying question is much bigger than one administration:

WHY CAN THE SAME MEDICINE COST SO DIFFERENTLY DEPENDING ON WHICH SIDE OF AN OCEAN YOU BUY IT?

For decades, Americans have watched prescription-drug prices become one of Washington’s recurring promises. Republicans and Democrats have proposed different solutions. Pharmaceutical companies argue that U.S. revenue helps finance expensive research and development; critics argue Americans have effectively subsidized lower prices elsewhere.

Now America is about to run a nationwide Medicaid experiment aimed directly at that imbalance.

Watch the sequence:

05.12.2025 // MFN EXECUTIVE ORDER
09.18.2026 // ALL 50 STATES
01.01.2027 // MODEL BEGINS

And watch what happens next.

Which manufacturers participate?

Which drugs enter the model?

Do the projected savings materialize?

Do patients actually see meaningful differences?

Those answers will matter far more than any political slogan surrounding the announcement.

Because beneath the headlines is a question millions of American families understand immediately:

If another developed country can negotiate a medicine for less, why should an American automatically pay more?

50 states are now preparing to test one answer.

50 // 529B // 01.01.27

The announcement is finished.

Now watch the receipts.

Share the numbers. Read the policy. Decide for yourself.

⟁

Subscribe @imPascalNajadi